HIB/DTPA VACCINE COMPOSITION AND METHODS OF PREPARATION

(19)

(11)

EP 1 066 053 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	13.12.2006 Bulletin 2006/50

(45)	Mention of the grant of the patent:
	09.08.2006 Bulletin 2006/32

(21)	Application number: 99915692.0

(22)	Date of filing: 22.03.1999

(51)

International Patent Classification (IPC):

A61K 39/295^(2006.01)
A61K 39/05^(2006.01)
A61K 39/09^(2006.01)
A61K 39/10^(2006.01)
A61K 39/13^(2006.01)

A61K 39/39^(2006.01)
A61K 39/08^(2006.01)
A61K 39/095^(2006.01)
A61K 39/102^(2006.01)
A61K 39/29^(2006.01)

(86)	International application number:
	PCT/EP1999/001959

(87)	International publication number:
	WO 1999/048525 (30.09.1999 Gazette 1999/39)

(54)	HIB/DTPA VACCINE COMPOSITION AND METHODS OF PREPARATION HIB/DTPA IMPFSTOFF UND HERSTELLUNGSMETHODEN COMPOSITION DE VACCIN CONTRE HIB/DTPA ET SES METHODES DE PREPARATION

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	SI

(30)

Priority:

25.03.1998 GB 9806456

(43)	Date of publication of application:
	10.01.2001 Bulletin 2001/02

(73)	Proprietor: GlaxoSmithKline Biologicals s.a.
	1330 Rixensart (BE)

(72)	Inventors:
	ARTOIS, Claude, Glaxosmithkline Biologicals S.A. B-1330 Rixensart (BE) DE HEYDER, Koen, Glaxosmithkline Biologicals S.A. B-1330 Rixensart (BE) DESMONS, Pierre, Glaxosmithkline Biologicals S.A. B-1330 Rixensart (BE) GARCON, Nathalie, Glaxosmithkline Biologicals S.A. B-1330 Rixensart (BE) MAINIL, Roland, Glaxosmithkline Biologicals S.A. B-1330 Rixensart (BE)

(74)	Representative: Dalton, Marcus Jonathan William et al
	GlaxoSmithKline Corporate Intellectual Property (CN9.25.1) 980 Great West Road Brentford, Middlesex TW8 9GS Brentford, Middlesex TW8 9GS (GB)

(56)

References cited: :

WO-A-93/24148
WO-A-97/46255

WO-A-97/00697

CORBEL M.J. ET AL: "Workshop on Standardisation of Aluminium Adsorbed Vaccines, Bergen, Norway, 21 June 1996." BIOLOGICALS, (1997) 25/3 (351-353). , XP002110484
CORBEL M J: "CONTROL TESTING OF COMBINED VACCINES: A CONSIDERATION OF POTENTIAL PROBLEMS AND APPROACHES" BIOLOGICALS, vol. 22, no. 4, 1 December 1994 (1994-12-01), pages 353-360, XP000603003 ISSN: 1045-1056
ELLIS R W: "Development of combination vaccines" VACCINE, vol. 17, no. 13-14, January 1999 (1999-01), page 1635-1642 XP004158298 ISSN: 0264-410X


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).